|
1
|
Luhn P and Wentzensen N: HPV-based tests
for cervical cancer screening and management of cervical disease.
Curr Obstet Gynecol Rep. 2:76–85. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Regan JA and Laimins LA: Viral
transformation of epithelial cells. Methods Mol Biol. 945:449–465.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Deberne M, Levy A, Mondini M, Dessen P,
Vivet S, Supiramaniam A, Vozenin MC and Deutsch E: The combination
of the antiviral agent cidofovir and anti-EGFR antibody cetuximab
exerts an antiproliferative effect on HPV-positive cervical cancer
cell lines’ in-vitro and in-vivo xenografts. Anticancer Drugs.
24:599–608. 2013.PubMed/NCBI
|
|
4
|
Srivastava S, Shahi UP, Dibya A, Gupta S
and Roy JK: Distribution of HPV genotypes and involvement of risk
factors in cervical lesions and invasive cervical cancer: a study
in an Indian population. Int J Mol Cell Med. 3:61–73.
2014.PubMed/NCBI
|
|
5
|
Huh W, Williams E, Bramley T, Huang J and
Poulios N: Cost-effectiveness of various combinations of human
papillomavirus (hpv)-based testing, including genotyping for hpv
16/18, for cervical cancer screening. Value Health. 16:A142–A143.
2013. View Article : Google Scholar
|
|
6
|
Racey CS, Withrow DR and Gesink D:
Self-collected HPV testing improves participation in cervical
cancer screening: a systematic review and meta-analysis. Can J
Public Health. 104:159–166. 2013.PubMed/NCBI
|
|
7
|
Sadraeian M, Rasoul-Amini S, Mansoorkhani
MJ, Mohkam M, Ghoshoon MB and Ghasemi Y: Induction of antitumor
immunity against cervical cancer by protein HPV-16 E7 in fusion
with ricin B chain in tumor-bearing mice. Int J Gynecol Cancer.
23:809–814. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Katki HA, Schiffman M, Castle PE,
Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage
JC and Kinney WK: Five-year risks of CIN 3+ and cervical cancer
among women who test Pap-negative but are HPV-positive. J Low Genit
Tract Dis. 17(5 Suppl 1): s56–s63. 2013.PubMed/NCBI
|
|
9
|
Xu Q, Yuan B, Xue F, et al: OPN gene
polymorphisms are associated with susceptibility and
clinicopatholigical characteristics of cervical cancer in a Chinese
cohort. Cancer Biomark. 10:233–239. 2011.PubMed/NCBI
|
|
10
|
Smola-Hess S, Pahne J, Mauch C, Zigrino P,
Smola H and Pfister HJ: Expression of membrane type 1 matrix
metalloproteinase in papillomavirus-positive cells: role of the
human papillomavirus (HPV) 16 and HPV8 E7 gene products. J Gen
Virol. 86:1291–1296. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Herfs M, Parra-Herran C, Howitt BE, Laury
AR, Nucci MR, Feldman S, et al: Cervical squamocolumnar
junction-specific markers define distinct, clinically relevant
subsets of low-grade squamous intraepithelial lesions. Am J Surg
Pathol. 37:1311–1318. 2013. View Article : Google Scholar
|
|
12
|
Wang S, Pang T, Gao M, Kang H, Ding W, Sun
X, Zhao Y, Zhu W, Tang X, Yao Y and Hu X: HPV E6 induces eIF4E
transcription to promote the proliferation and migration of
cervical cancer. FEBS Lett. 587:690–697. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Branković I, Verdonk P and Klinge I:
Applying a gender lens on human papillomavirus infection: cervical
cancer screening, HPV DNA testing, and HPV vaccination. Int J
Equity Health. 12:142013.PubMed/NCBI
|
|
14
|
Chang L, He X, Yu G and Wu Y:
Effectiveness of HPV 16 viral load and the E2/E6 ratio for the
prediction of cervical cancer risk among Chinese women. J Med
Virol. 85:646–654. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chu A, Genden E, Posner M and Sikora A: A
patient-centered approach to counseling patients with head and neck
cancer undergoing human papillomavirus testing: a clinician’s
guide. Oncologist. 18:180–189. 2013.
|
|
16
|
Priebe AM: 2012 cervical cancer screening
guidelines and the future role of HPV testing. Clin Obstet Gynecol.
56:44–50. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wentzensen N: Triage of HPV-positive women
in cervical cancer screening. Lancet Oncol. 14:107–109. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eide ML and Debaque H: HPV detection
methods and genotyping techniques in screening for cervical cancer.
Ann Pathol. 32:e15–e23. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ragin C, Obikoya-Malomo M, Kim S, Chen Z,
Flores-Obando R, Gibbs D, et al: HPV-associated lung cancers: an
international pooled analysis. Carcinogenesis. 35:1267–1275. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu Q, Xue F, Yuan B, Zhang L, Li J and He
Z: The interaction between RAGE gene polymorphisms and HPV
infection in determining the susceptibility of cervical cancer in a
Chinese population. Cancer Biomark. 11:147–153. 2012.PubMed/NCBI
|
|
21
|
Cox JT, Castle PE, Behrens CM, Sharma A,
Wright TC Jr and Cuzick J; Athena HPV Study Group. Comparison of
cervical cancer screening strategies incorporating different
combinations of cytology, HPV testing, and genotyping for HPV
16/18: results from the ATHENA HPV study. Am J Obstet Gynecol.
208:184.e1–184.e11. 2013.PubMed/NCBI
|
|
22
|
Sasagawa T, Takagi H and Makinoda S:
Immune responses against human papillomavirus (HPV) infection and
evasion of host defense in cervical cancer. J Infect Chemother.
18:807–815. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pilch H, Günzel S, Schäffer U, Tanner B,
Brockerhoff P, Maeurer M, et al: Human papillomavirus (HPV) DNA in
primary cervical cancer and in cancer free pelvic lymph nodes -
correlation with clinico-pathological parameters and prognostic
significance. Zentralbl Gynakol. 123:91–101. 2001. View Article : Google Scholar
|
|
24
|
Habbous S, Pang V, Eng L, Xu W, Kurtz G,
Liu FF, Mackay H, Amir E and Liu G: p53 Arg72Pro polymorphism, HPV
status and initiation, progression, and development of cervical
cancer: a systematic review and meta-analysis. Clin Cancer Res.
18:6407–6415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang N, Yin D, Zhang S, Wei H, Wang S and
Zhang Y, Lu Y, Dai S, Li W, Zhang Q and Zhang Y: TNF-alpha
rs1800629 polymorphism is not associated with HPV infection or
cervical cancer in the Chinese population. PLoS One. 7:e452462012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wiwanitkit V: Prevalence of HPV genotypes
in cervical cancer in Thailand. Int J Gynecol Cancer. 22:12902012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Markman M: Risk of cervical cancer after
HPV vaccination. Curr Pharm Des. 19:1488–1489. 2013.PubMed/NCBI
|
|
28
|
Fröberg M, Norman I, Johansson B, Hjerpe
A, Weiderpass E and Andersson S: Liquid-based cytology with HPV
triage of low-grade cytological abnormalities versus conventional
cytology in cervical cancer screening. Curr Pharm Des.
19:1406–1411. 2013.PubMed/NCBI
|
|
29
|
Sharma M, Bruni L, Diaz M, Castellsagué X,
de Sanjosé S, Bosch FX and Kim JJ: Using HPV prevalence to predict
cervical cancer incidence. Int J Cancer. 132:1895–1900. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Szarewski A: HPV vaccination and cervical
cancer. Curr Oncol Rep. 14:559–567. 2012. View Article : Google Scholar
|
|
31
|
Keller MJ, Burk RD, Xie X, Anastos K,
Massad LS, Minkoff H, Xue X, D’Souza G, Watts DH, Levine AM, et al:
Risk of cervical precancer and cancer among HIV-infected women with
normal cervical cytology and no evidence of oncogenic HPV
infection. JAMA. 308:362–369. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang CY, Chen JJ, Shen KY, Chang LS, Yeh
YC, Chen IH, Chong P, Liu SJ and Leng CH: Recombinant lipidated HPV
E7 induces a Th-1-biased immune response and protective immunity
against cervical cancer in a mouse model. PLoS One. 7:e409702012.
View Article : Google Scholar
|
|
33
|
Origoni M, Cristoforoni P, Costa S,
Mariani L, Scirpa P, Lorincz A and Sideri M: HPV-DNA testing for
cervical cancer precursors: from evidence to clinical practice.
Ecancermedicalscience. 6:2582012.PubMed/NCBI
|
|
34
|
Schmitz M, Driesch C, Jansen L, Runnebaum
IB and Dürst M: Non-random integration of the HPV genome in
cervical cancer. PLoS One. 7:e396322012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kaarthigeyan K: Cervical cancer in India
and HPV vaccination. Indian J Med Paediatr Oncol. 33:7–12. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Barbisan G, Pérez LO, Contreras A and
Golijow CD: TNF-α and IL-10 promoter polymorphisms, HPV infection,
and cervical cancer risk. Tumour Biol. 33:1549–1556. 2012.
|
|
37
|
Bosch FX, de Sanjosé S and Castellsagué X:
The prospects of HPV vaccination in cervical cancer prevention:
results of a new independent trial. Cancer Discov. 1:377–380. 2011.
View Article : Google Scholar : PubMed/NCBI
|
